A case of chronic hepatitis B with primary adefovir resistance;Adefovire primer dirençli bir kronik B hepatiti olgusu

Mikrobiyoloji Bulteni

Volumn 41, Issue 2, 2007, Pages 297-301

  Yamazhan, Tansu ^a   Sertöz, Rüçhan ^a   Pullukçu, Hüsnü ^a   Taşbakan, Meltem ^a   Ulusoy, Sercan ^a   Erensoy, Selda ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Adefovir; Hepatitis B; Primary resistance

Indexed keywords

ADEFOVIR; ADENINE; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; DRUG DERIVATIVE; LAMIVUDINE; PHOSPHONIC ACID DERIVATIVE; VIRUS DNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD; CASE REPORT; DRUG COMBINATION; DRUG EFFECT; GENETICS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE;

ADENINE; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; MALE; PHOSPHONIC ACIDS;

EID: 38549112114     PISSN: 03749096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-22.
2. Keeffe EB, Dieterich DT, Han HS, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4: 936-62.
3. Yang H, Westland CE, Delaney WE, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002; 36: 464-73.
4. Locarnini S. Hepatitis B viral resistance mechanisms and diagnosis. VIDRL (Victorian Infectious Disease Reference Laboratory) Conference Report (hbvadvocate.org/news/reports/locarnini.html).
5. Locarnini S, Shaw T, Sozzi T, et al. HBV mutants associated with clinical resistance to adefovir dipivoxil display only small decreases in antiviral sensitivity in vitro. Hepatology 2004; 40: 244A.
6. Tenney DJ, Langley DR, Oliver AJ, et al. Hepatitis B virus resistance to entecavir involves novel changes in the viral polymerase. Hepatology 2004; 40: 245A.
7. Schildgen O, Sirma H, Funk A, et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006; 354: 1807-12.
8. Hadziyannis SJ, Tassapoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-7.
9. Zoulim F, Poynard T, Degos F et al. A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. J Viral Hepat 2006; 4: 278-88.
10. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352: 2743-6.
11. Van Bömmel F, Wünsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; 40: 1421-5.
12. Colonno R. Entecavir two year resistance update: no resistance observed in nucleoside naive patients and low frequency resistance emergence in lamivudine refractory patients. 56th Annual Meeting of the American Association for the Study of Liver Diseases; November 11-15, 2005; San Francisco, California. Program and Abstracts Book, Abstract no: 962.